34 results about "Ferroportin" patented technology

The invention relates to novel salts of compounds of the general formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia, sickle cell disease and hemochromatosis.

The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

An L-amino acid is produced by culturing an L-amino acid-producing bacterium which belongs to the Enterobacteriaceae family and which has been modified so that the activity of an iron transporter is increased by enhancing expression of one or more genes of the following genes: tonB gene, fepA gene, and fecA.

The invention relates to materials and procedures for the use of the hepcidin binding domain (HBD) on ferroportin. A 20 amino acid peptide of the HBD was synthesized and shown to recapitulate the characteristics and specificity of hepcidin binding to cell surface ferroportin. The affinity of hepcidin for the HBD peptide permits a rapid, sensitive assay of hepcidin in biological fluids.

The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis. The compounds of Formula I and pharmaceutical salts thereof have the following structure:wherein R1, R2, R3, X1, X2, X3, X4, Y1, Y2, and Y3 are as described herein.

The invention discloses a short-interfering RNA for inhibiting human ferroportin from being expressed. The invention further discloses a DNA for encoding the corresponding shRNA of the short-interfering RNA and a recombinant capable of expressing the RNA. The short-interfering RNA, the DNA and the recombinant can effectively inhibit the expression of the human ferroportin inside body, as well as the release and the catabolism of iron and adjust the serum iron level inside body, thereby achieving the purpose of curing the related diseases of iron metabolism.

The invention relates to the field of plant molecular biology, in particular to a peanut ferrous transport protein gene as well as an encoding gene and application thereof. The invention discloses peanut ferrous transport protein AhNRAMP1 which is (1) a protein formed by an amino acid sequence shown as SEQ ID No.2, or (2) a protein formed by substituting, deleting or adding one or more amino acids in the amino acid sequence shown as SEQ ID No.2 and derived from (1), equal activity. The invention also discloses a gene for encoding the protein. The utilization efficiency on iron and the content of the iron in kernels can be improved by applying the new species of leguminous plants cultivated by the AhNRAMP1 provided by the invention.

A cell-based assay for identifying a compound that inhibits iron transport in Gram-negative bacteria, engineered bacterial cells, and kits for conducting the same. The assay involves contacting a candidate compound with an engineered Gram-negative bacteria in the presence of iron for a sufficient period of time, exposing the reaction solution to an energy source to generate the detectable signal, and detecting changes in the detectable signal in the reaction solution over time. The engineered Gram-negative bacteria comprises an iron transport protein on its outer membrane that comprises an amino acid residue that has been engineered with a detectable label that generates a detectable signal. The changes in the detectable signal in the assay system over time correspond to the effect of the candidate compound on iron transport in the Gram-negative bacteria.

The invention discloses the application of SPD_0310 protein as a target in the preparation of medicines for preventing and treating Streptococcus pneumoniae infection. In the present invention, it was found that the expression level of SPD_0310 in the triple mutant strain in which the three main iron transport genes of Streptococcus pneumoniae were knocked out at the same time was increased and could grow normally, indicating that the SPD_0310 protein may be involved in the interaction of various iron transport proteins. The present invention also found that the spd_0310 gene knockout strain has reduced infectivity to mice. Based on this, SPD_0310 can be used to prepare antibodies to the protein, so as to facilitate the development of antibody drugs. In addition, the present invention also found that the active center of the protein can bind heme, and proved that porphyrins can be used as substrates to compete with heme, indicating that porphyrins can be used as inhibitors of SPD_0310 to inhibit Streptococcus pneumoniae toxicity, which has broad application prospects in the field of antibacterial drugs.

The present invention relates to mutations in the gene coding for ferroportin 1 associated with hereditary haemochromatosis and methods for the diagnosis of hereditary haemochromatosis based on the identification of such mutations.

The present invention relates to mutations in the gene coding for ferroportin 1 associated with hereditary haemochromatosis and methods for the diagnosis of hereditary haemochromatosis based on the identification of such mutations.